Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here